FENC — Fennec Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $383.89m
- $342.64m
- $44.64m
Brief: Fennec Pharmaceuticals Reports Full Year And Fourth Quarter 2022 Financial Results
Fennec Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Fennec Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview
Fennec Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Ionis, PulteGroup, Atlas Technical, Tesla
U.S. STOCKS ON THE MOVE-A O Smith, Pentair, health insurers
Brief: Fennec Pharmaceuticals Says Pedmark Receives Orphan Drug Exclusivity From U.S. FDA
U.S. STOCKS ON THE MOVE-Spotify, McDonald's, Pfizer
Fennec rises on orphan drug exclusivity for hearing loss therapy
U.S. STOCKS ON THE MOVE-Hess Corp, Monro, MarketAxess
U.S. STOCKS ON THE MOVE-Block Inc, Fennec, Inhibikase Therapeutics
Fennec rises as medical body recommends co's hearing loss therapy
Brief: Fennec Updates NCCN Clinical Practice Guidelines, Recommend PEDMARK
Brief: Fennec Pharmaceuticals Files Prospectus Relates To Possible Resale Of Up To 3.9 Million Of Common Shares
Fennec Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Fennec Pharmaceuticals Reports Q3 Loss Of $0.31 Per Share
Fennec Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Fennec Pharma up after launch of hearing-loss therapy
Brief: Fennec Pharmaceuticals Announces Commercial Availability Of Pedmark (Sodium Thiosulfate Injection) In The U.S.